Treatment of Pulmonary Disorders with Retinoic Acid or Other Retinoids by Inducing Formation of Gas-Exchange Units (Alveoli)
Disclose Your Invention
Technologies for Licensing
Industry Collaboration Opportunities
Research and Clinical Trials
Office of Sponsored Research
Categories: “Respiratory Diseases“
Reference #: 1996-038
OTC Contact: Sharon E. Pula, Esq. (Directory Information | Send a Message)
The present invention relates to the treatment of Emphysema by using Retinoic acid, its esters and the analogues. These compounds, when administered, either bucally, sublingually or by nebulizer, result in enhancing alveolar function or development; and thus offer great therapeutic and commercial potential in treating pulmonary diseases involving alveolar dysfunction, such as emphysema.
The present technology offers first non-surgical means to treat emphysema.
Stage of Development
Proof-of-concept demonstrated in mice.
“Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats,” Massaro et al, Nature Medicine, vol. 3, No. 6,675-677 (1997).
“Postnatal treatment with retinoic acid increases the number of pulmonary alveoli in rats,” Massaro et al, Am. J. Physiol., 270, L305-L310 (1996).
Gloria De Carlo Massaro, and Donald Massaro
U.S. patents 5,998,486 and 6,277,890 “Treatment of Pulmonary Disorders with Retinoic Acid or Other Retinoids by Inducing Formation of Gas-Exchange Units (Alveoli)” Issued on December 9, 1999 and August 21, 2001.